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Summary. We evaluated the effect of r-hirudin and/or tissue-
plasminogen activator (t-PA) in a model of DIC in rabbits
induced by i.v. infusion of 100 mg/kg/h/6 h endotoxin. Rabbits
were treated with saline (endotoxin control group), r-hirudin at
0·3 mg/kg/h/6 h, t-PA at 0·3 mg/kg for 90 min and r-hirudin
plus t-PA at the doses described above. The best results were
achieved when r-hirudin and t-PA were infused together. This
treatment reduced the consumption of platelets and protein
C and attenuated the increase of PAI-1 more efficiently than
r-hirudin or t-PA alone. r-Hirudin plus t-PA also resulted in the
lowest formation of fibrin deposits in the kidneys. Finally,
mortality at 24 h dropped from 70% in the endotoxin control
group to 40%, 10% and 0% in the t-PA, r-hirudin and r-
hirudin plus t-PA groups respectively. None of the t-PA-infused
rabbits which had died by 24 h showed macroscopic signs of
haemorrhage. r-Hirudin alone was better than t-PA alone, as
was shown by fibrin deposits and mortality. We conclude that
r-hirudin and t-PA given simultaneously were more efficient
than either given alone in this model of DIC. Effective
thrombin inhibition, which could influence other pathophy-
siological mechanisms apart from coagulation, together with
the improvement in fibrinolysis, would explain these results.
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Gram-negative bacteria-induced sepsis frequently results in
disseminated intravascular coagulation (DIC) (Bick, 1992).
Despite the use of potent antibiotics and intensive supportive
care, the mortality remains close to 60% (Pa´ramo & Rocha,
1994).
Endotoxin or lipopolysaccharide (LPS), a constituent of the
outer membrane of Gram-negative bacteria, leads monocytes
and endothelial cells to generate several cytokines which
activate coagulation (Warr et al, 1990). The high amounts of
thrombin generated transform fibrinogen into fibrin and
stimulate platelet aggregation, leading to the raising of stable
microthrombi. On the other hand, the continuous thrombo-
genic stimuli induce the exhaustion of antithrombin III (AT
III) and protein C, the main coagulation inhibitors, thus
perpetuating fibrin generation (Marlar et al, 1982; Fenton,
1986) and allowing the appearance of microvascular thrombi
in various organs which subsequently results in multiple
organ failure (MOF) (Robboy et al, 1972). The dramatic
increase in plasminogen activator inhibitor-1 (PAI-1) in
these patients, with the subsequent inhibition of the main
fibrinolysis activator, tissue-type plasminogen activator (t-PA)
(Pa´ramo et al, 1988; Pa´ramo et al, 1990), leads to a hypo-
fibrinolytic state which could contribute to the persistence of
fibrin deposits.
Recombinant hirudin (r-hirudin), cloned from the medi-
cinal leech, Hirudo medicinalis, is a direct and selective
thrombin inhibitor able to effectively inhibit clot bound
thrombin (Weitz et al, 1990; Markward, 1991). r-Hirudin,
whose efficacy in venous and arterial thrombosis has been
widely studied (Ten-Cate, 1996), could be an attractive
therapeutic agent in LPS-induced DIC, as is suggested by
previous work in several experimental models (Ishikawa et
al, 1980; Hoffmann et al, 1990; Zawilska et al, 1993;
Dickneite & Czech, 1994; Dickneite et al, 1994; Hermida et
al, 1998). On the other hand, fibrinolytic activators have
been found to be useful in different animal models of
thrombosis and DIC (Matsuo et al, 1981; Korninger et al,
1982; Collen et al, 1983; Agnelli et al, 1985; Schneider,
1993; Paloma et al, 1995; Hardaway et al, 1996). Therefore
a treatment which combines an antithrombotic agent and a
thrombolytic could be a promising therapeutic strategy in
DIC. The aim of the present work was to study the
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beneficial effects, if any, of treating LPS-induced DIC rabbits
with r-hirudin and t-PA simultaneously, when compared
with rabbits treated with r-hirudin alone or t-PA alone.
Mortality and kidney fibrin deposition are evaluated and the
changes in some coagulation and fibrinolytic parameters are
assessed as secondary end-points.
MATERIAL AND METHODS
Material. LPS (E. coli 0111:B4) was obtained from Difco
Laboratories (Detroit, U.S.A.). Recombinant desulphatohir-
udin variant 1 (RevascTM, specific activity 115 000 ATU/mg)
was from Ciba-Geigy (Switzerland). t-PA (ActyliseTM), was
purchased from Boehringer Ingelheim (Germany).
Experimental model. Male New Zealand white rabbits
(weight 2–3 kg) were used. Animals were anaesthetized by
an intramuscular injection of 30 mg/kg ketamin hydro-
chloride and 0·002 mg/kg xylacine hydrochloride followed
by intramuscular boosts of ketamin hydrochloride through-
out the experiment. 10 rabbits were infused with saline at
20 ml/h for 6 h as a first saline control group. DIC was
induced in rabbits by intravenous infusion of 100 mg/kg/h
LPS for 6 h in 60 ml (10 ml/h) saline through the marginal
ear vein.
Treatments started simultaneously with LPS infusion
through the contralateral marginal ear vein. Four different
groups (10 rabbits each) were established: LPS group: saline
as placebo (10 ml/h) for 6 h; r-hirudin group: 0·3 mg/kg/h
r-hirudin for 6 h; t-PA group: 0·3 mg/kg t-PA for 90 min;
r-hirudin þ t-PA group: 0·3 mg/kg/h r-hirudin for 6 h þ
0·3 mg/kg t-PA for 90 min.
Surviving rabbits were killed 24 h after the start of
treatment by intravenous injection of 60 mg/kg Nembutal
(Abbot Laboratories, U.S.A.). Kidneys were extracted from all
animals (survivors and non-survivors) for subsequent
histological studies.
Laboratory methods. Blood samples were taken through a
catheter inserted into a femoral artery immediately before
LPS infusion, and 2 and 6 h after the start. Blood for platelet
counts was collected in tubes containing K3-EDTA. Stabilyte
tubes (Biopool, Umea, Sweden) were used in order to avoid
inhibitor interference to collect blood for t-PA activity. The
rest of the samples were collected in 3·2% citrate to
determine fibrinogen, AT III, protein C, plasminogen, PAI-1
and t-PA activity: blood was kept on ice for no longer than
2 h and platelet-poor plasma obtained by centrifugation at
1600 g for 20 min at 48C and stored at ¹708C until assay.
A Counter STKS automatic analyser (Coulter Corp.,
Hialeah, Fla., U.S.A.) was used to count platelets. Fibrinogen
was measured by Clauss’s method (Clauss, 1957). Commer-
cially available assays based on chromogenic substrates were
used to determine AT III (Abilgaard et al, 1976), protein C
(Vinazzer & Pangraz, 1987), plasminogen (Krishnamurti et
al, 1987), t-PA activity (Verheijen et al, 1982) and PAI-1
activity (Pa´ramo et al, 1985) (Coamatic AT III, Coamatic
Protein C, Coamatic Plasminogen, Coaset t-PA and Coatest
PAI, Chromogenix, Stockholm, Sweden).
Histological examination. Kidney sections were fixed in
formalin, embedded in paraffin, stained with Masson’s
trichrome and examined for the presence of fibrin micro-
thrombi by a pathologist unaware of the experimental
design. Tissue sections were scored on a scale from 0 to 4 as
previously described (Go´mez et al, 1989). Briefly: (0) no
fibrin; (1) partial fibrin deposits in some glomeruli; (2) partial
deposits in all glomeruli; (3) large quantities of fibrin in all
glomeruli; (4) fibrin thrombi in glomerular capillaries and in
non-capillary vessels.
Data analysis. Within groups: The Student t-test for paired
data and the Wilcoxon test for paired data were used to
compare baseline values of the haemostatic parameters with
values at 2 and 6 h. Between groups: Results of the
haemostatic parameters at 2 and 6 h were converted to
percentages assuming a value of 100% for baseline data, and
were expressed as mean 6 standard error of the mean (SEM).
The Kruskal-Wallis test followed by the Mann-Whitney U test
was applied for purposes of group comparison. Differences in
mortality rate at 24 h were assessed by the Fisher’s exact
test. Differences in kidney fibrin deposits were determined by
the Kruskal-Wallis test followed by the Mann-Whitney U test.
RESULTS
Haemostatic parameters during the experiment
in the different groups
No changes in the saline control group were observed during
the experiment (data not shown). Table I shows the plasma
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Table I. Haemostatic parameters at baseline and 2 and 6 h after the start of the LPS infusion
in the LPS group (n ¼ 10).
Baseline 2 h 6 h
Platelets ( · 109/l) 454 6 40 226 6 33*** 97 6 21***
Fibrinogen (g/l) 2·78 6 0·31 2·48 6 0·25 1·58 6 0·17**
AT III (U/ml) 1·17 6 0·03 1·03 60·05** 0·85 6 0·06**
Protein C (U/ml) 1·42 6 0·05 0·84 6 0·08*** 0·23 6 0·05***
Plasminogen (U/ml) 0·84 6 0·03 0·75 6 0·04* 0·64 6 0·04***
t-PA (U/ml) 0·60 6 0·02 0·41 6 0·03*** 0·35 6 0·04**
PAI-1 (U/ml) 30·5 6 0·7 172 6 3*** 361 6 10***
* P<0·05, ** P<0·01, *** P<0·001 when compared with basal values.
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levels of haemostatic parameters during the experiment in
the LPS group and Table II shows the haemostatic
parameters at 2 and 6 h in the LPS and treatment groups.
Effect of treatments on LPS-induced changes
in coagulation parameters
The simultaneous addition of r-hirudin and t-PA was the
most efficient treatment to reduce platelets and protein C
consumption; r-hirudin, alone as well as with t-PA, partially
prevented the platelet drop observed in the LPS group at 2
and at 6 h and the simultaneous infusion of r-hirudin and t-
PA was more efficient than r-hirudin alone at 2 h (P<0·05)
and than t-PA alone at both 2 (P <0·05) and 6 h (P<0·01)
(Fig 2A); moreover, although all treatments significantly
attenuated the protein C consumption assessed in the LPS
group at 2 and 6 h (Fig 2B), r-hirudin and t-PA given
simultaneously were more efficient than r-hirudin alone at
2 h (P <0·05). The decrease in the AT III consumption
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Fig 1. Kidney fibrin deposits (score values expressed as mean 6 SEM)
and mortality rate (expressed as the percentage of non-survivors
rabbits) in the LPS group and all treatment groups. * P<0·05,
** P<0·01 and ***P<0·001 as compared to the LPS group;
§ P<0·05 as compared to the r-hirudin þ t-PA group.
shown by the LPS group at 6 h was partially prevented both
by the r-hirudin and t-PA treatment and by t-PA alone, but
not by r-hirudin alone. Finally, there were no differences
between groups in fibrinogen levels at 2 h and all treatments
significantly reduced its consumption at 6 h.
Effect of treatments on LPS-induced changes
in fibrinolytic parameters
As expected, t-PA was markedly increased (P<0·001) at 2 h in
both t-PA treatment groups and was still raised at 6 h with
respect to the LPS group. Rabbits treated with r-hirudin alone
also showed higher t-PA levels than the LPS group at 6 h,
although the amounts of activator measured were not as high
as in the t-PA-infused rabbits. Although a reduction in the
increase of PAI-1 levels at 2 h was achieved with all treatments
(Fig 2C), such reduction was significantly higher (P<0·05) in
the rabbits given r-hirudin and t-PA simultaneously than in the
rabbits treated with r-hirudin alone. However, the changes
were never dramatic. Finally, there were no changes in
plasminogen between groups along the experiment.
Effect of treatments on kidney fibrin deposits and mortality rate
Rabbits infused with saline did not show kidney fibrin
deposits. Intense deposits of fibrin within glomerular
capillaries were observed in the LPS group rabbits (score
2·61 6 0·34, expressed as mean 6 SEM). As shown in the
top panel of Fig 1, although all treatments significantly
reduced the kidney fibrin deposits with respect to the LPS
group, a higher reduction was achieved when r-hirudin and
t-PA were infused simultaneously (score 0·31 6 0·21,
P <0·001) than when r-hirudin and t-PA were given alone
(scores 0·83 6 0·35, P <0·01 and 1·30 6 0·42, P <0·05
respectively). However, the scores of the r-hirudin alone and
t-PA alone groups were not significantly different from the
score of the r-hirudin plus t-PA group, which is probably
because of the relatively small number of rabbits included in
the study.
As far as mortality is concerned, it must be noted firstly
that none of the rabbits had died at the end of the 6 h of
endotoxin and treatment infusion, which enabled us to rule
out the possibility that death by 24 h, when it occurred, was
anaesthesia-related. All rabbits infused with saline survived.
7/10 rabbits which were infused with LPS without treatment
had died by the first 24 h after the start of the experiment, as
shown in the bottom panel of Fig 1. 4/10 rabbits died when
t-PA was given alone, which produced in a mortality rate not
significantly lower than that obtained in the LPS group.
However, mortality significantly decreased when rabbits
were treated with r-hirudin, and the results were similar
when r-hirudin was infused alone (only 1/10 died, P<0·05)
to when it was given with t-PA (none of them died, P <0·01).
Mortality in the latter group was also significantly lower
(P<0·05) than that achieved in the rabbits infused with t-PA
alone, which, on the other hand, did not show macroscopic
signs of haemorrhage (nor did the rabbits from the other
groups) in the post-mortem examination.
DISCUSSION
The effect of the simultaneous administration of r-hirudin
and t-PA to rabbits given LPS to induce DIC was compared
with the effect of the infusion of r-hirudin or t-PA alone. As in
experiments previously performed by our group (Go´mez et al,
1989; Paloma et al, 1992, 1995; Hermida et al, 1998), a
significant impairment in the haemostatic parameters as
well as an intense kidney fibrin deposition and a high
mortality rate were assessed following LPS infusion in
rabbits.
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Fig 2. Haemostatic parameters at 2 and 6 h in the LPS group and all treatment groups. Values are expressed as the mean 6 SEM percent of the
initial value before LPS infusion. * P<0·05, ** P<0·01 and ***P<0·001 as compared to the LPS group; ‡ P<0·05, ‡ ‡ P<0·01 as compared to
the r-hirudin þ t-PA group.
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r-Hirudin given alone, in agreement with previous reports
(Ishikawa et al, 1980; Hoffmann et al, 1990; Dickneite et al,
1994; Hermida et al, 1998), reduced the consumption of
platelets, fibrinogen, AT III and protein C but also attenuated
the increase of PAI-1 at 2 h, which could be due to a lower
stimulation of its thrombin-mediated release from the
endothelium (Gelerther & Sznycer-Laszuk, 1986; Bevilacqua
et al, 1986; Van Hinsberg et al, 1988). PAI-1 was not reduced
at 6 h which was probably due to the action of tumour
necrosis factor-a (TNF-a) which would induce a retarded,
sustained PAI-1 increase, although some controversy about
the relationship between TNF-a and PAI-1 exists (Emeis et al,
1995). The overall result of treating rabbits with r-hirudin
was a significant reduction in kidney fibrin deposits and a
significant decrease in the mortality rate. Taking into
account the fact that a previous report showed that the
mortality reduction could not be explained merely by an
effect on the haemostatic system (Taylor et al, 1991), it is
tempting to speculate that the improvement in some
haemostatic markers that we have assessed in this study
could prevent other inflammatory responses apart from
coagulation (Ten-Cate et al, 1996).
When rabbits were treated with t-PA alone, the availability
of this fibrinolytic activator in plasma at 2 h was greatly
improved, in agreement with our previous experiments
(Paloma et al, 1995). As a result, the PAI-1 increase
subsequent to LPS infusion was partially reduced 2 h after
the start of the experiment due to the formation of t-PA–PAI-
1 complexes. However, since t-PA was given only for the first
90 min and taking into account the fact that the activator is
rapidly removed from the circulation (Krause, 1988), this
treatment was not able to reduce the notable PAI-1 increase
at 6 h. On the other hand, these changes in the fibrinolytic
profile were accompanied by a reduction in the consumption
of protein C, AT III and fibrinogen. Kidney fibrin deposits at
24 h were decreased, in agreement with our previous data
(Paloma et al, 1995). However, the mortality rate was not
significantly reduced, suggesting again that lethality cannot
be explained merely by the haemostatic imbalance.
The simultaneous administration of r-hirudin and t-PA to
rabbits improved the haemostatic markers to a higher degree
than any of the other treatments, especially protein C and
PAI-1. As these rabbits showed fewer kidney fibrin deposits
than the other groups, these data are in agreement with
previous reports where we demonstrated a strong direct
correlation between protein C consumption or PAI-1
increase and severity of kidney fibrin deposition (Go´mez et
al, 1989; Hermida et al, 1998). The remarkable reduction in
the renal fibrin deposits assessed in these rabbits would be
due, on the one hand, to the thrombin inhibition and, on the
other hand, to the fibrinolytic improvement. None of the
rabbits infused with t-PA and r-hirudin had died by the first
24 h, in contrast with the animals given t-PA alone (4/10 did
not survive). This observation, taken together with the fact
that only 1/10 rabbits infused with r-hirudin alone died,
seems to indicate that the effective thrombin inhibition by
r-hirudin is a key to survival in this model.
In the light of our results we conclude that treatment with
r-hirudin and t-PA given simultaneously markedly improved
the haemostatic markers and reduced kidney fibrin deposits
and mortality in our model of LPS-induced DIC, being more
efficient than the treatment with r-hirudin or t-PA alone.
Effective thrombin inhibition, together with the fibrinolytic
improvement, would explain these results. The mortality
assessed in the rabbits treated with t-PA alone indicates that
the transient improvement in t-PA availability, although able
partially to reduce the renal fibrin deposition, is not enough
to reduce lethality in this model. The good results obtained in
the rabbits treated with r-hirudin alone show that the
efficient thrombin inhibition greatly counteracts the lethal
effects of endotoxaemia, probably not merely by an effect on
the coagulation system but also by an effect on other host
responses in which some coagulation markers (e.g. protein
C) may be involved, although further work is needed to
assess this point.
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